enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant drop in short interest in October. As of October 15th, there was short interest totalling 2,500 shares, a drop of 81.3% from the September 30th total of 13,400 shares. Based on an average trading volume of 3,900 shares, the short-interest ratio is currently 0.6 days.

enGene Price Performance

enGene stock traded down $0.03 during midday trading on Friday, hitting $2.07. The company’s stock had a trading volume of 1,092 shares, compared to its average volume of 20,150. enGene has a 12 month low of $0.39 and a 12 month high of $6.50. The stock’s 50-day moving average price is $1.48 and its 200-day moving average price is $2.06.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.